This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wilson PW et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837–1847
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285: 2486–2497
Michos ED et al. (2005) Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. Am Heart J 150: 1276–1281
Ridker PM et al. (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352: 1293–1304
American Heart Association (2007) Heart Disease and Stroke Statistics–2007 Update [http://www.americanheart.org/downloadable/heart/11721754590102007%20Stat%20charts%20Circ%20Final%20v2.ppt#2] (accessed 16 April 2007)
Mosca L et al. (2007) Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115: 1481–1501
Acknowledgements
The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has participated in trial steering committees for and received research grants and contracts from Merck, National Heart, Lung, and Blood Institute, and Pfizer. She has acted as a Consultant for Abbott, AstraZeneca, Bristol-Myers Squibb, CV Therapeutics, GlaxoSmithKline, Merck, NitroMed, Sanofi-Aventis, and Schering-Plough and has participated in the Speakers Bureau (CME only) for Bristol-Myers Squibb, CV Therapeutics, Eli Lilly, Merck, NitoMed, Novartis, and Pfizer.
Rights and permissions
About this article
Cite this article
Wenger, N. The Reynolds Risk Score: improved accuracy for cardiovascular risk prediction in women?. Nat Rev Cardiol 4, 366–367 (2007). https://doi.org/10.1038/ncpcardio0913
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0913
This article is cited by
-
The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women
Cardiovascular Drugs and Therapy (2015)
-
Therapeutic options for premature coronary artery disease
Current Treatment Options in Cardiovascular Medicine (2008)